DevsHealth has announced The Hacking Bacteria’s Project, which aims to in kind invest up to one million euros on antibiotics’ R&D projects during next three years. With this project, the new CataloniaBio &HealthTech member will collaborate with biotech and pharma companies as well as academic research groups to use its technology and expertise to boost antibiotic development projects. 

Each year, 330,000 people die from an infection due to bacteria resistant to antibiotics, a number that is expected to grow up to 10 million a year by 2050. Invest in antibiotics development is not profitable for pharmaceutical companies because an average investment is around $1.5 billion and expected sales for an antibiotic are around $46 millions per year. In fact, last entirely original class of antibiotic was discovered in the late 1980s.

With the Hacking Bacteria’sProject, DevsHealth will select potential projects at early development to offer company’s technology and knowledge. It will be done through a commercial project with, at least, 50% discount. Total investment will be up to one million euros through a total of 40 projects, 7 during 2022, 13 in 2023 and 20 in 2024. To make future development easier, DevsHealth will not retain any intellectual property right over the project.

DevsHealth, is a bioinformatics company that develops machine learning (AI) and real-world data (RWD) based methods for computational drug development. Working together with partners to develop better drugs for all people.

Click here for more information.

Photo: Alfons Nonell-Canals, CEO DevsHealth